DOCSLIB.ORG

Ceutical Chemistry

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ceutical Chemistry molecules Current Aspects of Radiopharma- ceutical Chemistry Edited by Peter Brust Printed Edition of the Special Issue Published in Molecules www.mdpi.com/journal/molecules Current Aspects of Radiopharmaceutical Chemistry Current Aspects of Radiopharmaceutical Chemistry Special Issue Editor Peter Brust MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade Special Issue Editor Peter Brust Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig Germany Editorial Office MDPI St. Alban-Anlage 66 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal Molecules (ISSN 1420-3049) from 2017 to 2018 (available at: http://www.mdpi.com/journal/molecules/ special issues/Radiopharmaceutical Chemistry) For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Article Number, Page Range. ISBN 978-3-03897-162-7 (Pbk) ISBN 978-3-03897-163-4 (PDF) Cover image courtesy of Helmholtz-Zentrum Dresden-Rossendorf. Articles in this volume are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book taken as a whole is c 2018 MDPI, Basel, Switzerland, distributed under the terms and conditions of the Creative Commons license CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/). Contents About the Special Issue Editor ...................................... vii Preface to ”Current Aspects of Radiopharmaceutical Chemistry” ................. ix Nikunj B. Bhatt, Darpan N. Pandya and Thaddeus J. Wadas Recent Advances in Zirconium-89 Chelator Development Reprinted from: Molecules 2018, 23, 638, doi: 10.3390/molecules23030638 .............. 1 J´an Kozempel, Olga Mokhodoeva and Martin Vlk Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators Reprinted from: Molecules 2018, 23, 581, doi: 10.3390/molecules23030581 .............. 25 Licia Uccelli, Alessandra Boschi, Petra Martini, Corrado Cittanti, Stefania Bertelli, Doretta Bortolotti, Elena Govoni, Luca Lodi, Simona Romani, Samanta Zaccaria, Elisa Zappaterra, Donatella Farina, Carlotta Rizzo, Melchiore Giganti and Mirco Bartolomei Influence of Storage Temperature on Radiochemical Purity of 99mTc-Radiopharmaceuticals Reprinted from: Molecules 2018, 23, 661, doi: 10.3390/molecules23030661 .............. 43 Sara Roslin, Peter Brandt, Patrik Nordeman, Mats Larhed, Luke R. Odell and Jonas Eriksson Synthesis of 11C-Labelled Ureas by Palladium(II)-Mediated Oxidative Carbonylation Reprinted from: Molecules 2017, 22, 1688, doi: 10.3390/molecules22101688 ............. 51 Tetsuro Tago and Jun Toyohara Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases Reprinted from: Molecules 2018, 23, 300, doi: 10.3390/molecules23020300 .............. 72 Susann Schr¨oder, Barbara Wenzel, Winnie Deuther-Conrad, Rodrigo Teodoro, Mathias Kranz, Matthias Scheunemann, Ute Egerland, Norbert H¨ofgen, Detlef Briel, J¨org Steinbach and Peter Brust Investigation of an 18F-labelled Imidazopyridotriazine for Molecular Imaging of Cyclic Nucleotide Phosphodiesterase 2A Reprinted from: Molecules 2018, 23, 556, doi: 10.3390/molecules23030556 .............. 99 Nicolas Vignal, Salvatore Cisternino, Nathalie Rizzo-Padoin, Carine San, Fortune Hontonnou, Thibaut Gel´e, Xavier Decl`eves, Laure Sarda-Mantel and Benoˆıt Hosten [18F]FEPPA a TSPO Radioligand: Optimized Radiosynthesis and Evaluation as a PET Radiotracer for Brain Inflammation in a Peripheral LPS-Injected Mouse Model Reprinted from: Molecules 2018, 23, 1375, doi: 10.3390/molecules23061375 .............114 Bieneke Janssen, Danielle J. Vugts, Albert D. Windhorst and Robert H. Mach PET Imaging of Microglial Activation—Beyond Targeting TSPO Reprinted from: Molecules 2018, 23, 607, doi: 10.3390/molecules23030607 ..............130 Friedrich-Alexander Ludwig, Steffen Fischer, Ren´e Smits, Winnie Deuther-Conrad, Alexander Hoepping, Solveig Tiepolt, Marianne Patt, Osama Sabri and Peter Brust Exploring the Metabolism of (+)-[18F]Flubatine In Vitro and In Vivo: LC-MS/MS Aided † Identification of Radiometabolites in a Clinical PET Study Reprinted from: Molecules 2018, 23, 464, doi: 10.3390/molecules23020464 ..............144 v Teresa Mann, Jens Kurth, Alexander Hawlitschka, Jan Stenzel, Tobias Lindner, Stefan Polei, Alexander Hohn, Bernd J. Krause and Andreas Wree 18 [ F]Fallypride-PET/CT Analysis of the Dopamine D2/D3 Receptor in the Hemiparkinsonian Rat Brain Following Intrastriatal Botulinum Neurotoxin A Injection Reprinted from: Molecules 2018, 23, 587, doi: 10.3390/molecules23030587 ..............159 Mathias Kranz, Ralf Bergmann, Torsten Kniess, Birgit Belter, Christin Neuber, Zhengxin Cai, Gang Deng, Steffen Fischer, Jiangbing Zhou, Yiyun Huang, Peter Brust, Winnie Deuther-Conrad and Jens Pietzsch Bridging from Brain to Tumor Imaging: (S)-(−)- and (R)-(+)-[18F]Fluspidine for Investigation of † Sigma-1 Receptors in Tumor-Bearing Mice Reprinted from: Molecules 2018, 23, 702, doi: 10.3390/molecules23030702 ..............177 Cristina M ¨uller, Patrycja Guzik, Klaudia Siwowska, Susan Cohrs, Raffaella M. Schmid and Roger Schibli Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates Reprinted from: Molecules 2018, 23, 1465, doi: 10.3390/molecules23061465 .............190 vi About the Special Issue Editor Peter Brust, Prof., Dr., is a biologist. He received his M.S. in Immunology in 1981 and his Ph.D. in Neuroscience from Leipzig University in 1986. He worked as a postdoctoral fellow at Montreal Neurological Institute and Johns Hopkins University, Baltimore, from 1990 to 1991. He joined the Research Center Rossendorf (now known as Helmholtz-Zentrum Dresden-Rossendorf, HZDR) in 1992 and headed the Department of Biochemistry. Since 2002, he has been working in Leipzig, first at the Institute of Interdisciplinary Isotope Research and, after an operational transfer in 2010, again at the HZDR, where he leads the Department of Neuroradiopharmaceuticals. His main research interest is in radiotracer development for brain imaging with positron emission tomography, including brain tumor imaging (glioblastoma, brain metastases), imaging of blood-brain barrier transport of radiopharmaceuticals, and neuroimaging of the cholinergic system, second-messenger systems, and neuromodulatory processes. He has about 250 peer-reviewed publications and owns numerous patents. vii Preface to ”Current Aspects of Radiopharmaceutical Chemistry” Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are in vivo molecular imaging techniques which are widely used in nuclear medicine for the diagnosis and treatment follow-up of many major diseases. They use target-specific molecules as probes, which are labeled with radionuclides of short half-lives, synthesized prior to the imaging studies. These probes are called radiopharmaceuticals. Their design and development require a rather interdisciplinary process involving many different disciplines of natural sciences and medicine. In addition to their diagnostic and therapeutic applications in the field of nuclear medicine, radiopharmaceuticals are powerful tools for in vivo pharmacology during the process of pre-clinical drug development to identify new drug targets, investigate the pathophysiology of diseases, discover potential drug candidates, and evaluate the pharmacokinetics and pharmacodynamics of drugs in vivo. Furthermore, they allow molecular imaging studies in various small-animal models of disease, including genetically engineered animals. The current collection of articles provides unique examples covering all major aspects in the field. The first half, radiopharmacy, is more chemistry- related, while the second half, radiopharmacology, deals with the preclinical development of radiopharmaceuticals. The largest proportion of positron-emitting radionuclides is commonly produced in particle 68 68 accelerators, usually cyclotrons. More recently, generator systems, e.g., the Ge/ Ga generator, have shown great potential as a source of positron-emitting radionuclides for PET. Gallium-68, which has a relatively short half-life (68 min), is particularly suitable for the labeling of peptides that show rapid target tissue accumulation and clearance. PET investigation of monoclonal antibodies, which represent one of the fastest growing therapeutic groups, requires radionuclides with much longer half-lives. The decay half-life of zirconium-89 (3.3 d) matches the circulation half-lives of antibodies (usually in the order of days); therefore, it emerged as a suitable PET radionuclide for labeling. The review of Bhatt et al. focuses on recent advances in zirconium-89 chelation chemistry. Another major use of radiometals is in radionuclide therapy of cancer. Radium-223, an alpha- emitting radionuclide, has been approved for the treatment of bone metastasis in metastatic castration-resistant prostate cancer. In vivo generators are thought to combine the long half-life of a parent radionuclide with the high decay energy of the daughter to achieve high-dose targeted radiotherapy. On the other hand, they
Load more

Recommended publications
  • Radiation Dosimetry of the Α4β2 Nicotinic Receptor Ligand (+)-[18F
    Kranz et al. EJNMMI Physics (2016) 3:25 EJNMMI Physics DOI 10.1186/s40658-016-0160-5 ORIGINAL RESEARCH Open Access Radiation dosimetry of the α4β2 nicotinic receptor ligand (+)-[18F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results Mathias Kranz1†, Bernhard Sattler2†, Solveig Tiepolt2, Stephan Wilke2, Winnie Deuther-Conrad1, Cornelius K. Donat1,4, Steffen Fischer1, Marianne Patt2, Andreas Schildan2, Jörg Patt2, René Smits3, Alexander Hoepping3, Jörg Steinbach1, Osama Sabri2† and Peter Brust1*† * Correspondence: [email protected] †Equal contributors Abstract 1 Institute of Radiopharmaceutical 18 Cancer Research, Research Site Background: Both enantiomers of [ F]flubatine are new radioligands for neuroimaging Leipzig, Helmholtz-Zentrum of α4β2 nicotinic acetylcholine receptors with positron emission tomography (PET) Dresden-Rossendorf, exhibiting promising pharmacokinetics which makes them attractive for different clinical Permoserstraße 15, 04318 Leipzig, 18 Germany questions. In a previous preclinical study, the main advantage of (+)-[ F]flubatine 18 Full list of author information is compared to (−)-[ F]flubatine was its higher binding affinity suggesting that available at the end of the article 18 (+)-[ F]flubatine might be able to detect also slight reductions of α4β2 nAChRs and could be more sensitive than (−)-[18F]flubatine in early stages of Alzheimer’s disease. To support the clinical translation, we investigated a fully image-based internal dosimetry approach for (+)-[18F]flubatine, comparing mouse data collected on a preclinical PET/MRI system to piglet and first-in-human data acquired on a clinical PET/CT system. Time-activity curves (TACs) were obtained from the three species, the animal data extrapolated to human scale, exponentially fitted and the organ doses (OD), and effective dose (ED) calculated with OLINDA.
    [Show full text]
  • Acetylcholine Signaling System in Progression of Lung Cancers
    Pharmacology & Therapeutics 194 (2019) 222–254 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Acetylcholine signaling system in progression of lung cancers Jamie R. Friedman a,1, Stephen D. Richbart a,1,JustinC.Merritta,KathleenC.Browna, Nicholas A. Nolan a, Austin T. Akers a, Jamie K. Lau b, Zachary R. Robateau a, Sarah L. Miles a,PiyaliDasguptaa,⁎ a Department of Biomedical Sciences, Joan C. Edwards School of Medicine, 1700 Third Avenue, Huntington, WV 25755 b Biology Department, Center for the Sciences, Box 6931, Radford University, Radford, Virginia 24142 article info abstract Available online 3 October 2018 The neurotransmitter acetylcholine (ACh) acts as an autocrine growth factor for human lung cancer. Several lines of evidence show that lung cancer cells express all of the proteins required for the uptake of choline (choline Keywords: transporter 1, choline transporter-like proteins) synthesis of ACh (choline acetyltransferase, carnitine acetyl- Lung cancer transferase), transport of ACh (vesicular acetylcholine transport, OCTs, OCTNs) and degradation of ACh (acetyl- Acetylcholine cholinesterase, butyrylcholinesterase). The released ACh binds back to nicotinic (nAChRs) and muscarinic Cholinergic receptors on lung cancer cells to accelerate their proliferation, migration and invasion. Out of all components Proliferation of the cholinergic pathway, the nAChR-signaling has been studied the most intensely. The reason for this trend Invasion Anti-cancer drugs is due to genome-wide data studies showing that nicotinic receptor subtypes are involved in lung cancer risk, the relationship between cigarette smoke and lung cancer risk as well as the rising popularity of electronic ciga- rettes considered by many as a “safe” alternative to smoking.
    [Show full text]
  • Final Opinion on Additives Used in Tobacco Products
    Tobacco Additives II Final Scientific Committee on Health, Environmental and Emerging Risks SCHEER Opinion on Additives used in tobacco products (Opinion 2) Tobacco Additives II The SCHEER approved this Opinion by written procedure on 16 December 2016. 1 Tobacco Additives II Final Opinion About the Scientific Committees (2016-2021) Two independent non-food Scientific Committees provide the Commission with the scientific advice it needs when preparing policy and proposals relating to consumer safety, public health and the environment. The Committees also draw the Commission's attention to the new or emerging problems which may pose an actual or potential threat. They are: the Scientific Committee on Consumer Safety (SCCS) and the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER). The Scientific Committees review and evaluate relevant scientific data and assess potential risks. Each Committee has top independent scientists from all over the world who are committed to work in the public interest. In addition, the Commission relies upon the work of other Union bodies, such as the European Food Safety Authority (EFSA), the European Medicines Agency (EMA), the European Centre for Disease prevention and Control (ECDC) and the European Chemicals Agency (ECHA). SCHEER This Committee, on request of Commission services, provides Opinions on questions concerning health, environmental and emerging risks. The Committees addresses questions on: - health and environmental risks related to pollutants in the environmental media and other biological and physical factors in relation to air quality, water, waste and soils. - complex or multidisciplinary issues requiring a comprehensive assessment of risks to consumer safety or public health, for example antimicrobial resistance, nanotechnologies, medical devices and physical hazards such as noise and electromagnetic fields.
    [Show full text]
  • Altered Neural Cholinergic Receptor Systems in Cocaine-Addicted Subjects
    Neuropsychopharmacology (2010) 35, 1485–1499 & 2010 Nature Publishing Group All rights reserved 0893-133X/10 $32.00 www.neuropsychopharmacology.org Altered Neural Cholinergic Receptor Systems in Cocaine-Addicted Subjects ,1,2 3 1 1,2 3 Bryon Adinoff* , Michael D Devous Sr , Mark J Williams , Susan E Best , Thomas S Harris , 4 1 1 Abu Minhajuddin , Tanya Zielinski and Munro Cullum 1 2 Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA; VA North Texas Health Care System, Dallas, TX, 3 4 USA; Nuclear Medicine Center and Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA Changes in the brain’s cholinergic receptor systems underlie several neuropsychiatric disorders, including Alzheimer’s disease, schizophrenia, and depression. An emerging preclinical literature also reveals that acetylcoholine may have an important function in addictive processes, including reward, learning, and memory. This study was designed to assess alterations in cholinergic receptor systems in limbic regions of abstinent cocaine-addicted subjects compared with healthy controls. On three separate days, 23 1- to 6-week abstinent, cocaine- (and mostly nicotine-) addicted subjects and 22 sex-, age-, and race-matched control subjects were administered the muscarinic and nicotinic cholinergic agonist physostigmine, the muscarinic antagonist scopolamine, and saline. Regional cerebral blood flow (rCBF) after each infusion was determined using single photon emission-computed tomography. Both cholinergic probes induced rCBF changes (po0.005) in relatively distinct, cholinergic-rich, limbic brain regions. After physostigmine, cocaine-addicted subjects showed altered rCBF, relative to controls, in limbic regions, including the left hippocampus, left amygdala, and right insula.
    [Show full text]
  • HDAC Neuroimaging Enabled by [18F]-Fluorination Methodology
    Impacting Neuroscience With Chemistry: HDAC Neuroimaging Enabled by [18F]-Fluorination Methodology The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Strebl, Martin Georg. 2017. Impacting Neuroscience With Chemistry: HDAC Neuroimaging Enabled by [18F]-Fluorination Methodology. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:42061502 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Impacting Neuroscience With Chemistry: HDAC Neuroimaging Enabled by [18F]-Fluorination Methodology A thesis presented by Martin Georg Strebl to The Department of Chemistry and Chemical Biology in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Chemistry and Chemical Biology Harvard University Cambridge, Massachusetts June 2017 ©2017 - Martin Georg Strebl All rights reserved. Thesis advisor Author Jacob Hooker and Tobias Ritter Martin Georg Strebl Impacting Neuroscience With Chemistry: HDAC Neuroimaging Enabled by [18F]-Fluorination Methodology Abstract In this dissertation, innovative radiochemical methodology was leveraged to systemat- ically advance radiotracer development. A novel organometallic radiofluorination was established, as
    [Show full text]
  • Nicotinic Filtering of Sensory Processing in Auditory Cortex
    UC Irvine UC Irvine Previously Published Works Title Nicotinic filtering of sensory processing in auditory cortex Permalink https://escholarship.org/uc/item/846470hj Journal Frontiers in Behavioral Neuroscience, 6 ISSN 1662-5153 Authors Metherate, Raju Intskirveli, Irakli Kawai, Hideki D Publication Date 2012-07-19 DOI 10.3389/fnbeh.2012.00044 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California REVIEW ARTICLE published: 19 July 2012 BEHAVIORAL NEUROSCIENCE doi: 10.3389/fnbeh.2012.00044 Nicotinic filtering of sensory processing in auditory cortex Raju Metherate 1*, Irakli Intskirveli 1 and Hideki D. Kawai 2 1 Department of Neurobiology and Behavior, Center for Hearing Research, University of California, Irvine, Irvine, CA, USA 2 Faculty of Engineering, Department of Bioinformatics, Soka University, Hachiouji, Tokyo, Japan Edited by: Although it has been known for decades that the drug nicotine can improve cognitive Anita Disney, Salk Institute for function, the nature of its effects and the underlying mechanisms are not well understood. Biological Studies, USA Nicotine activates nicotinic acetylcholine (ACh) receptors (nAChRs) that normally are Reviewed by: activated by endogenous ACh, presumably “hijacking” the cholinergic contribution to Jean-Marc Edeline, Université de Paris, France multiple cognitive functions, notably attention. Thus, studying nicotine’s effects helps to Alex Thiele, Newcastle University, better understand a commonly used drug as well as functions of nAChRs. Moreover, UK nicotinic agonists are being developed to treat a variety of disorders that involve *Correspondence: attention-related or age-related cognitive dysfunction. Studies have shown that nicotine Raju Metherate, Department of can enhance processing of attended stimuli and/or reduce processing of distracters; Neurobiology and Behavior, Center for Hearing Research, University of that is, nicotine enhances attentional filtering.
    [Show full text]
  • PET Imaging of A4b2* Nicotinic Acetylcholine Receptors: Qualitative Analysis of 18F-Nifene Kinetics in the Nonhuman Primate
    Journal of Nuclear Medicine, published on July 31, 2012 as doi:10.2967/jnumed.112.103846 PET Imaging of a4b2* Nicotinic Acetylcholine Receptors: Qualitative Analysis of 18F-Nifene Kinetics in the Nonhuman Primate Ansel T. Hillmer1,2, Dustin W. Wooten1,2, Maxim S. Slesarev2, Elizabeth O. Ahlers2, Todd E. Barnhart1, Dhanabalan Murali1,2, Mary L. Schneider3, Jogeshwar Mukherjee4, and Bradley T. Christian1,2,5 1Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin; 2Waisman Brain Imaging Laboratory, University of Wisconsin-Madison, Madison, Wisconsin; 3Department of Kinesiology, University of Wisconsin-Madison, Madison, Wisconsin; 4Department of Radiological Sciences, University of California-Irvine, Irvine, California; and 5Department of Psychiatry, University of Wisconsin-Madison, Madison, Wisconsin Key Words: nAChR; PET; nicotine; 18F-nifene; compartment The PET radioligand 2-fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyr- modeling idine (18F-nifene) is an a4b2* nicotinic acetylcholine receptor J Nucl Med 2012; 53:1–10 (nAChR) agonist developed to provide accelerated in vivo equi- DOI: 10.2967/jnumed.112.103846 librium compared with existing a4b2* radioligands. The goal of this work was to analyze the in vivo kinetic properties of 18F- nifene with both kinetic modeling and graphical analysis tech- niques. Methods: Dynamic PET experiments were performed on 4 rhesus monkeys (female; age range, 9–13 y) using a small- animal PET scanner. Studies began with a high-specific-activity uch work in the last 15 y has been devoted toward 18 18 M F-nifene injection, followed by a coinjection of F-nifene and developing suitable PET radioligands to image a4b2* nico- unlabeled nifene at 60 min.
    [Show full text]
  • Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases
    molecules Review Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases Tetsuro Tago and Jun Toyohara * ID Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo 173-0015, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-3-3964-3241; Fax: +81-3-3964-1148 Received: 1 January 2018; Accepted: 29 January 2018; Published: 31 January 2018 Abstract: Epigenetic alterations of gene expression have emerged as a key factor in several neurodegenerative diseases. In particular, inhibitors targeting histone deacetylases (HDACs), which are enzymes responsible for deacetylation of histones and other proteins, show therapeutic effects in animal neurodegenerative disease models. However, the details of the interaction between changes in HDAC levels in the brain and disease progression remain unknown. In this review, we focus on recent advances in development of radioligands for HDAC imaging in the brain with positron emission tomography (PET). We summarize the results of radiosynthesis and biological evaluation of the HDAC ligands to identify their successful results and challenges. Since 2006, several small molecules that are radiolabeled with a radioisotope such as carbon-11 or fluorine-18 have been developed and evaluated using various assays including in vitro HDAC binding assays and PET imaging in rodents and non-human primates. Although most compounds do not readily cross the blood-brain barrier, adamantane-conjugated radioligands tend to show good brain uptake. Until now, only one HDAC radioligand has been tested clinically in a brain PET study. Further PET imaging studies to clarify age-related and disease-related changes in HDACs in disease models and humans will increase our understanding of the roles of HDACs in neurodegenerative diseases.
    [Show full text]
  • Micropet/CT Imaging of [18F]-FEPPA in the Nonhuman Primate: a Potential Biomarker of Pathogenic Processes Associated with Anesthetic-Induced Neurotoxicity
    International Scholarly Research Network ISRN Anesthesiology Volume 2012, Article ID 261640, 11 pages doi:10.5402/2012/261640 Research Article MicroPET/CT Imaging of [18F]-FEPPA in the Nonhuman Primate: A Potential Biomarker of Pathogenic Processes Associated with Anesthetic-Induced Neurotoxicity Xuan Zhang,1 Merle G. Paule,1 Glenn D. Newport,1 Fang Liu,1 Ralph Callicott,1 Shuliang Liu,1 Marc S. Berridge,2, 3 Scott M. Apana,2, 3 William Slikker Jr.,1 and Cheng Wang1 1 National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA 2 3D Imaging, LLC, Little Rock, AR 72113, USA 3 University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA Correspondence should be addressed to Cheng Wang, [email protected] Received 6 August 2012; Accepted 15 September 2012 Academic Editors: J. Abraini and J.-H. Baumert Copyright © 2012 Xuan Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. The inhalation anesthetics nitrous oxide (N2O) and isoflurane (ISO) are used in surgical procedures for human infants. Injury to the central nervous system is often accompanied by localization of activated microglia or astrocytosis at the site of injury. The tracer that targets to the peripheral benzodiazepine receptor (PBR), [18F]N-2-(2-fluoroethoxy)benzyl)- N-(4-phenoxypyridin-3-yl)acetamide ([18F]-FEPPA), has been reported as a sensitive biomarker for the detection of neuronal damage/inflammation. Methods. On postnatal day (PND) 5 or 6 rhesus monkey neonates were exposed to a mixture of N2O/oxygen and ISO for 8 hours and control monkeys were exposed to room air.
    [Show full text]
  • Development of Novel Radiotracers for Pet Imaging of Hdac-Mediated Epigenetic Regulation Robin Edwards Bonomi Wayne State University
    Wayne State University Wayne State University Dissertations 1-1-2016 Development Of Novel Radiotracers For Pet Imaging Of Hdac-Mediated Epigenetic Regulation Robin Edwards Bonomi Wayne State University, Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations Part of the Biomedical Engineering and Bioengineering Commons Recommended Citation Bonomi, Robin Edwards, "Development Of Novel Radiotracers For Pet Imaging Of Hdac-Mediated Epigenetic Regulation" (2016). Wayne State University Dissertations. 1519. https://digitalcommons.wayne.edu/oa_dissertations/1519 This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. DEVELOPMENT OF NOVEL RADIOTRACERS FOR PET IMAGING OF HDAC- MEDIATED EPIGENETIC REGULATION by ROBIN E. BONOMI DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2016 MAJOR: BIOMEDICAL ENGINEERING Approved By: Advisor: Juri G. Gelovani, M.D., Ph.D. Date Zhifeng Kou, Ph.D. Date Anthony Shields, M.D. Ph.D, Date Matthew Allen, Ph.D. Date ACKNOWLEDGEMENTS I would like to express immense gratitude and appreciation to my advisor, Dr. Juri Gelovani, for his mentorship and continuous commitment to helping me become a better scientist. I would like to thank my committee members, Dr. Anthony Shields, Dr. Zhifeng Kou, and Dr. Matthew Allen for their insights and opinions in imaging and chemistry. I would also like to thank the entire Gelovani Group for their support and participation in this work, including Dr. Aleksandr Shavrin, Dr.
    [Show full text]
  • The Therapeutic Potential of Epigenetic Modifications in Alzheimer’S Disease
    9 The Therapeutic Potential of Epigenetic Modifications in Alzheimer’s Disease Enric Bufill1 • Roser Ribosa-Nogué2 • Rafael Blesa2 1Neurology Department, Vic University Hospital, Vic, Spain; 2Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain Author for correspondence: Enric Bufill, Neurology Department, Vic University Hospital, Vic, Spain. Email: [email protected] Doi: https://doi.org/10.36255/exonpublications.alzheimersdisease.2020.ch9 Abstract: Alzheimer’s disease is characterized by the formation and deposit of abnormal peptides such as amyloid plaques and neurofibrillary tangles in the brain. Therapeutic strategies aimed at preventing the formation of such deposits have not been successful. Currently, there are no effective treatments for the disease. Since numerous epigenetic changes have been detected in Alzheimer’s disease, treatments aimed at reversing these changes by intervening in DNA meth- ylation, histone acetylation, and microRNA expression may constitute promising lines of research in the future. This chapter provides an overview of the epigenetic changes and the potential epigenetic therapies in Alzheimer’s disease. Keywords: Alzheimer’s disease; DNA methyltransferase; epigenetic changes; histone acetylation; noncoding RNA In: Alzheimer’s Disease: Drug Discovery. Huang X (Editor). Exon Publications, Brisbane, Australia. ISBN: 978-0-6450017-0-9; Doi: https://doi.org/10.36255/exonpublications.alzheimersdisease.2020 Copyright: The Authors. License: This open access article is licenced under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/ 151 152 Bufill E et al. INTRODUCTION Alzheimer’s disease (AD) is the most common cause of dementia.
    [Show full text]
  • Novel Biomarkers in Alzheimer's Disease
    Novel Biomarkers Novel in Alzheimer’s Disease • Chiara Villa Novel Biomarkers in Alzheimer’s Disease Edited by Chiara Villa Printed Edition of the Special Issue Published in Journal of Personalized Medicine www.mdpi.com/journal/jpm Novel Biomarkers in Alzheimer’s Disease Novel Biomarkers in Alzheimer’s Disease Editor Chiara Villa MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade • Manchester • Tokyo • Cluj • Tianjin Editor Chiara Villa University of Milano-Bicocca Italy Editorial Office MDPI St. Alban-Anlage 66 4052 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal Journal of Personalized Medicine (ISSN 2075-4426) (available at: https://www.mdpi.com/journal/ jpm/special issues/Biomarkers Alzheimer). For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Volume Number, Page Range. ISBN 978-3-03943-903-4 (Hbk) ISBN 978-3-03943-904-1 (PDF) c 2020 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND. Contents About the Editor .............................................. ix Chiara Villa Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going? Reprinted from: J.
    [Show full text]